18 Biotechnology Stocks to Sell Now

18 Biotechnology Stocks to Sell Now

This week, 18 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This is a rough week for Juno Therapeutics, Inc. (JUNO). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings surprise and return on equity. For more information, get Portfolio Grader’s complete analysis of JUNO stock.

Eagle Pharmaceuticals, Inc.’s (EGRX) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in sales growth, earnings growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of EGRX stock.

Alder Biopharmaceuticals, Inc. (ALDR) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of ALDR stock.

This week, OncoMed Pharmaceuticals, Inc. (OMED) drops from a C to a D rating. The company also gets F’s in sales growth, earnings revisions, earnings surprise, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OMED stock.

Concert Pharmaceuticals, Inc. (CNCE) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in sales growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of CNCE stock.

Slipping from a C to a D rating, Ascendis Pharma A/S Sponsored ADR (ASND) takes a hit this week. The company also gets F’s in sales growth, earnings growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ASND stock.

Immune Design Corp. (IMDZ) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMDZ stock.

This week, Vanda Pharmaceuticals Inc.’s (VNDA) rating worsens to a D from the company’s C rating a week ago. Vanda Pharmaceuticals Inc. is a biopharmaceutical company focusing on the development and commercialization of clinical-stage drug candidates for central nervous system disorders, with worldwide commercial rights to two product candidates in clinical development. The company also gets F’s in operating margin growth, earnings revisions, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of VNDA stock.

Tobira Therapeutics, Inc. (TBRA) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TBRA stock.

Ardelyx, Inc. (ARDX) slips from a C to a D this week. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARDX stock.

Ignyta, Inc. (RXDX) declines this week from a C to a D. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RXDX stock.

ImmunoGen, Inc.’s (IMGN) rating weakens this week, dropping to a D versus last week’s C. ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company also gets F’s in earnings surprise and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMGN stock.

Aldeyra Therapeutics, Inc. (ALDX) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALDX stock.

Anthera Pharmaceuticals, Inc. (ANTH) earns a D this week, moving down from last week’s grade of C. Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing anti-inflammatory therapeutics for cardiovascular diseases, lupus and other serious diseases. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ANTH stock.

This is a rough week for CorMedix Inc. (CRMD). The company’s rating falls to D from the previous week’s C. CorMedix Inc. is a development-stage pharmaceutical company that seeks to fulfill selected, significant unmet medical needs in the therapeutic areas at the crossroads of cardiac and kidney (renal) disease. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CRMD stock.

Slipping from a D to a F rating, Windtree Therapeutics, Inc. (WINT) takes a hit this week. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of WINT stock.

RXi Pharmaceuticals Corporation (RXII) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RXII stock.

This week, AmpliPhi BioSciences Corporation (APHB) drops from a C to a D rating. The company also gets F’s in operating margin growth, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of APHB stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/06/18-biotechnology-stocks-to-sell-now-3/.

©2019 InvestorPlace Media, LLC